Yu Liu1, Gang Jin2, Jingjing Sun1, Xue Wang3, Litao Guo4. 1. Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 2. Emergency Department, Xi'an Aerospace General Hospital. 3. Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: sci2014@126.com. 4. Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: glt2002@xjtu.edu.cn.
Abstract
BACKGROUND: Sepsis causes varying degrees of thrombocytopenia that are closely related to the likelihood of patient mortality. We analysed the effect of recombinant human thrombopoietin (rhTPO) on the platelet count in critically ill patients with sepsis-associated thrombocytopenia and provided a reference for its treatment. MATERIAL/ METHODS: The study was a retrospective analysis of the clinical data of patients. Patients were divided into an rhTPO group and control group according to the rhTPO use during treatment. Demographical and clinical data (age, sex, history of hypertension, diabetes, platelet counts, mortality rate et al.) of the patients were collected and analysed using statistical software; p<0.05 was considered statistically significant. RESULTS: Of 213 patients, 84 patients constituted the rhTPO group and 129 constituted the control group. The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01±18.23×109/L vs 36.31±14.17×109/L, p=0.003), fifth day (71.51±39.59×109/L vs. 42.95±20.48×109/L, p<0.001), and seventh day (115.36±69.41×109/L vs. 62.54±42.70×109/L, p<0.001). Further statistical analysis of the data of patients with platelet counts ≤30×109/L and>30×109/L and APACHE II scores>15 and ≤15 at the time of diagnosis showed that the increase in platelet counts in the rhTPO group was greater. There was no significant difference between the two groups in volume of platelet transfusions (rhTPO group 15.42±17.20 vs control group 10.93±17.48, p=0.068). The cost of ICU treatment in patients with rhTPO was higher (126,936.21±86,548.27 vs. 101,685.28±77,291.75 RMB, p=0.027); however, the ICU stay time was shorter (9.20±5.38 vs 10.88±6.82, p=0.047). There was no significant difference in 28-days mortality (rhTPO group: 25.0% vs control group: 34.1%, p=0.158) between the two groups. CONCLUSION: For patients with severe thrombocytopenia or patients with severe sepsis, rhTPO is efficacious in increasing the patients' platelet counts, resulting in a shorter ICU stay time.
BACKGROUND:Sepsis causes varying degrees of thrombocytopenia that are closely related to the likelihood of patientmortality. We analysed the effect of recombinant humanthrombopoietin (rhTPO) on the platelet count in critically illpatients with sepsis-associated thrombocytopenia and provided a reference for its treatment. MATERIAL/ METHODS: The study was a retrospective analysis of the clinical data of patients. Patients were divided into an rhTPO group and control group according to the rhTPO use during treatment. Demographical and clinical data (age, sex, history of hypertension, diabetes, platelet counts, mortality rate et al.) of the patients were collected and analysed using statistical software; p<0.05 was considered statistically significant. RESULTS: Of 213 patients, 84 patients constituted the rhTPO group and 129 constituted the control group. The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01±18.23×109/L vs 36.31±14.17×109/L, p=0.003), fifth day (71.51±39.59×109/L vs. 42.95±20.48×109/L, p<0.001), and seventh day (115.36±69.41×109/L vs. 62.54±42.70×109/L, p<0.001). Further statistical analysis of the data of patients with platelet counts ≤30×109/L and>30×109/L and APACHE II scores>15 and ≤15 at the time of diagnosis showed that the increase in platelet counts in the rhTPO group was greater. There was no significant difference between the two groups in volume of platelet transfusions (rhTPO group 15.42±17.20 vs control group 10.93±17.48, p=0.068). The cost of ICU treatment in patients with rhTPO was higher (126,936.21±86,548.27 vs. 101,685.28±77,291.75 RMB, p=0.027); however, the ICU stay time was shorter (9.20±5.38 vs 10.88±6.82, p=0.047). There was no significant difference in 28-days mortality (rhTPO group: 25.0% vs control group: 34.1%, p=0.158) between the two groups. CONCLUSION: For patients with severe thrombocytopenia or patients with severe sepsis, rhTPO is efficacious in increasing the patients' platelet counts, resulting in a shorter ICU stay time.